Gilead’s Irish business sees profit slump on falling sales of Covid drug

  • 📰 IrishTimes
  • ⏱ Reading Time:
  • 29 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 98%

HIV ข่าว

Hepatitis C

Business which accounts for close to one-third of group sales also took in €437m in dividends from subsidiaries dotted worldwide

therapy fell sharply. However, the Irish business took in $460 million in dividends from other companies in the group. Gilead Sciences Ireland has wholly-owned subsidiaries in 19 countries across Europe as well as In Australia, New Zealand, China, Singapore, Malaysia, Korea, Russia, Israel and central and South America.

Gilead has operations in Cork and Dublin which between them employ 635 people, according to results filed recently at the Companies Office. The company has a manufacturing, packaging and distribution centre in Cork that is responsible for close to a third of the group’s global supply of oral drugs for conditions like HIV and hepatitis C to around 100 markets worldwide.

Revenues dropped 10 per cent last year to $6.55 billion but that was enough to knock almost 60 per cent of profit after tax, which fell to $241.2 million from $593.5 million in 2022.

เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:

 /  🏆 3. in TH
 

ขอบคุณสำหรับความคิดเห็นของคุณ ความคิดเห็นของคุณจะถูกเผยแพร่หลังจากได้รับการตรวจสอบแล้ว

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว